REG-Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to evaluate petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer. Genmab will conduct the Phase 1/2 study, while Incyte will co-fund the trial and supply INCB161734, sharing development cost and risk.
Key figures
- Drug Name
- petosemtamab (GEN1158)
- Phase Of Trial
- Phase 1/2
- Indication
- first-line KRAS G12D-mutated metastatic colorectal cancer
- Combination agent
- INCB161734 (KRAS G12D inhibitor)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.